In silico analysis and experimental validation of azelastine hydrochloride (N4) targeting sodium taurocholate co-transporting polypeptide (NTCP) in HBV therapy

Cell Proliferation

Volumn 47, Issue 4, 2014, Pages 326-335

  Fu, L L ^a   Liu, J ^b   Chen, Y ^b   Wang, F T ^a,b   Wen, X ^a,b   Liu, H Q ^a,b   Wang, M Y ^a,b   Ouyang, L ^b   Huang, J ^c   Bao, J K ^a   Wei, Y Q ^b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AZELASTINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; POLYPEPTIDE; TAUROCHOLIC ACID; ZINC;

ANTIVIRAL ACTIVITY; ARTICLE; COMPUTER MODEL; CYTOTOXICITY; DRUG TARGETING; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; LABORATORY; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PHYLOGENY; RAT; SIMULATION;

HEPATITIS B VIRUS;

ANIMALS; ANTIVIRAL AGENTS; COMPUTER SIMULATION; DRUG DESIGN; HEP G2 CELLS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; PHTHALAZINES; PHYLOGENY; SYMPORTERS;

EID: 84903781583     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/cpr.12117     Document Type: Article

References (42)

1. Liu B, Wen X, Huang CH, Wei YQ (2013) Unraveling the complexity of hepatitis B virus: from molecular understanding to therapeutic strategy in 50 years. Int. J. Biochem. Cell Biol. 45, 1987-1996.
2. Fattovich G, Bortolotti F, Donato F (2008) Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J. Hepatol. 48, 335-352.
3. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F et al. (2013) Reprint of: epidemiological serosurvey of Hepatitis B in China - declining HBV prevalence due to Hepatitis B vaccination. Vaccine 31, J21-J28.
4. Zoulim F (2005) New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J. Hepatol. 42, 302-308.
5. Liang TJ (2009) Hepatitis B: the virus and disease. Expert Rev. Anti. Infect. Ther. 7, 309-320.
6. Urban S, Schulze A, Dandri M, Petersen J (2010) The replication cycle of hepatitis B virus. J. Hepatol. 52, 282-284.
7. Kao JH (2008) Diagnosis of hepatitis B virus infection through serological and virological markers. Expert Rev. Gastroenterol. Hepatol. 2, 553-562.
8. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G et al. (2005) Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352, 2682-2695.
9. Schiff ER, Dienstag JL, Karayalcin S, Grimm IS, Perrillo RP, Husa P et al. (2003) Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J. Hepatol. 38, 818-826.
10. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M et al. (2005) Long-term therapy with adefovirdipivoxil for HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 352, 2673-2681.
11. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC et al. (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354, 1001-1010.
12. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL et al. (2009) 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136, 486-495.
13. Hayashi K, Katano Y, Takeda Y, Honda T, Ishigami M, Itoh A et al. (2007) Comparison of hepatitis B virus subgenotypes in patients with acute and chronic hepatitis B and absence of lamivudine-resistant strains in acute hepatitis B in Japan. J. Med. Virol. 79, 366-373.
14. Robert MF (2008) Clinical uses of interferons. Br. J. Clin. Pharmacol. 65, 158-162.
15. Schulze A, Schieck A, Ni Y, Mier W, Urban S (2010) Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. J. Virol. 84, 1989-2000.
16. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z et al. (2012) Sodium taurocholateco transporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 1, e00049.
17. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 28, 2731-2739.
18. Higgins DG, Sharp PM (1988) CLUSTAL: a package for performing multiple sequence alignment on a microcomputer. Gene 73, 237-244.
19. Page RD (1996) TreeView: an application to display phylogenetic trees on personal computers. Comput. Appl. Biosci. 12, 357-358.
20. Mishra GR, Suresh M, Kumaran K, Kannabiran N, Suresh S, Bala P et al. (2006) Human protein reference database-2006 update. Nucleic Acids Res. 34, D411-D414.
21. Alfarano C, Andrade CE, Anthony K, Bahroos N, Bajec M, Bant-oft K et al. (2005) The Biomolecular Interaction Network Data-base and related tools 2005 update. Nucleic Acids Res. 33, D418-D424.
22. Kerrien S, Alam-Faruque Y, Aranda B, Bancarz I, Bridge A, De-row C et al. (2007) IntAct-open source resource for molecular interaction data. Nucleic Acids Res. 35, D561-D565.
23. Persico M, Ceol A, Gavrila C, Hoffmann R, Florio A, Cesareni G (2005) HomoMINT: an inferred human network based on orthology mapping of protein interactions discovered in model organisms. BMC Bioinformatics 6(Suppl. 4), S21.
24. Winter AG, Wildenhain J, Tyers M (2011) BioGRID REST Service, BiogridPlugin2 and BioGRIDWebGraph: new tools for access to interaction data at BioGRID. Bioinformatics 27, 1043-1044.
25. Xenarios I, Rice DW, Salwinski L, Baron MK, Marcotte EM, Ei-senberg D (2000) DIP: the database of interacting proteins. Nucleic Acids Res. 28, 289-291.
26. Wang N, Xu HL, Zhao X, Wen X, Wang FT, Wang SY et al. (2012) Network-based identification of novel connections among apoptotic signaling pathways in cancer. Appl. Biochem. Biotechnol. 167, 621-631.
27. Torsten S, Jürgen K, Nicolas G, Manuel CP (2003) SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res. 31, 3381-3385.
28. Fu LL, Yang Y, Xu HL, Cheng Y, Wen X, Ouyang L et al. (2013) Identification of novel caspase/autophagy-related gene switch to cell fate decisions in breast cancers. Cell Prolif. 46, 67-75.
29. Lang PT, Brozell SR, Mukherjee S, Pettersen EF, Meng EC, Thomas V et al. (2009) DOCK 6: combining techniques to model RNA-small molecule complexes. RNA 15, 1219-1230.
30. Dolinsky TJ, Czodrowski P, Li H, Nielsen JE, Jensen JH, Klebe G et al. (2007) PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations. Nucleic Acids Res. 35, W522-W525.
31. Pronk S, Páll S, Schulz R, Larsson P, Bjelkmar P, Apostolov R et al. (2013) GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 29, 845-854.
32. Schüttelkopf AW, van Aalten DM (2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 60, 1355-1363.
33. Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J. Mol. Graph. 14, 33-8, 27-28.
34. Huang KL, Lai YK, Lin CC, Chang JM (2006) Inhibition of hepatitis B virus production by Boehmerianivea root extract in HepG2.2.15 cells. World J. Gastroenterol. 12, 5721-5725.
35. Wu JM, Lin JS, Xie N, Liang KH (2003) Inhibition of hepatitis B virus by a novel L-nucleoside, beta-L-D4A and related analogues. World J. Gastroenterol. 9, 1840-1843.
36. Zhang T, Xie N, He W, Liu R, Lei Y, Chen Y et al. (2013) An integrated proteomics and bioinformatics analyses of hepatitis B virus X interacting proteins and identification of a novel interactorapoA-I. J. Proteomics 84, 92-105.
37. Hanazaki K (2004) Antiviral therapy for chronic hepatitis B: a review. Curr. Drug Targets Inflamm. Allergy 3, 63-70.
38. Zollner G, Wagner M, Fickert P, Silbert D, Fuchsbichler A, Zatloukal K et al. (2005) Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int. 25, 367-379.
39. Kullak-Ublick GA, Glasa J, Böker C, Oswald M, Grützner U, Hagenbuch B et al. (1997) Chlorambucil-taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas. Gastroenterology 113, 1295-1305.
40. Lee S, Kim S (2007) Gene regulations in HBV-related liver cirrhosis closely correlate with disease severity. J. Biochem. Mol. Biol. 40, 814-824.
41. Watashi K, Urban S, Li W, Wakita T (2014) NTCP and beyond: opening the door to unveil hepatitis B virus entry. Int. J. Mol. Sci. 15, 2892-2905.
42. Li H, Zhuang Q, Wang Y, Zhang T, Zhao J, Zhang Y et al. (2014) HBV life cycle is restricted in mouse hepatocytes expressing human NTCP. Cell. Mol. Immunol. 11, 175-183.